Simon Wilkinson himself has previously indicated a range of $500m-$1b, or around $2-$4 per share (I think it was in one of his recent video interviews). However if we get the hoped-for "RDGO" result, and we also have competing bidders amongst the big pharma companies, maybe it might just go for more? Anyway, let's just hope for a good trial result first... so far I'm seeing nothing but good (albeit anecdotal) evidence that MIS416 works, so I am optimistic about where things are going. In hindsight I bought in a couple of years too early but she's paying off nicely now. I don't expect any more share price fireworks now until we get closer to mid 2017 but if there are keen buyers still lurking, who knows.
IIL Price at posting:
70.0¢ Sentiment: Hold Disclosure: Held
